Danaher (DHR) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
9 Jul, 2026Opening remarks and agenda
Meeting called to order by the Chairman, with agenda and procedures available online.
Directors and the independent auditor from Ernst & Young LLP were introduced.
Record date for voting was March 7, 2025, and proper notice and proxy statements were confirmed.
Board and executive committee updates
Board nominees for director positions were presented for election to serve until the 2026 Annual Meeting.
Shareholder proposals
No shareholder proposals or additional matters were introduced for consideration.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Danaher
- Q3 sales and adjusted EPS grew; FY 2026 EPS guidance rose to $8.57–$8.62.DHR
Q3 2026 - Emerging markets drove growth, with localization and local reach central to expansion.DHRInvestor update
- Q2 2026 revenue up 5.5%, net earnings $870M, and full-year EPS guidance raised.DHRQ2 2026
- All proposals passed with strong support amid robust financial performance and strategic focus.DHRAGM 2026
- Strong growth in bioprocessing and diagnostics supports a positive full-year outlook.DHRBank of America Global Healthcare Conference 2026
- Bioprocessing and diagnostics drive growth outlook, with Masimo acquisition boosting long-term returns.DHRTD Cowen 46th Annual Health Care Conference
- Q1 2026 revenue up 3.5% to $6.0B, adjusted EPS up 9.5%, Masimo acquisition announced.DHRQ1 2026
- Strong 2025 results, robust recurring revenue, and innovation drive long-term growth outlook.DHRCorporate presentation
- Strong Q4 results, robust recurring revenue, and high single-digit growth outlook driven by innovation.DHR43rd Annual J.P. Morgan Healthcare Conference 2025